INNOVATING SIMPLIFIED
THROMBECTOMY SOLUTIONS
iCHOR is developing simple, smart technologies to transform the treatment of peripheral vascular occlusions
Solving Large Unmet Needs
Arterial and venous disease of the lower limbs affects millions of patients, has significant mortality rates, and has an enormous economic impact to our health care system. Patients often wait until symptoms are near irreversible, which is a primary reason why amputations rates are so high—globally more than 200,000 amputations per year are related to peripheral arterial disease (PAD). In addition, it is estimated that more than 400,000 lower limbs are treated for deep vein thrombosis (DVT) annually and are responsible for 60,000 to 100,000 deaths per year. Of the DVT patient population, 10% to 30% will die within 1 month of diagnosis and one-third of all people with DVT will have recurrence within 10 years.
At iCHOR, we want to make scientific contributions that improve outcomes and make a difference for patients. Specifically, our aim is to give vascular interventionalists versatile tools to treat a wide range of peripheral vascular occlusions while addressing the shortcomings of today’s drug, surgical, and mechanical treatment options.
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair. They identified an opportunity to develop new technologies to address these large unmet needs in treating peripheral vascular occlusions. This collaboration has lead to the development of the iSWEEP platform technology that has converted the tried and true Fogarty balloon sweep technique from an open surgery to a simple, minimally-invasive endovascular procedure.
We started iCHOR with the mission to become the first line therapy for peripheral vascular occlusions by developing simple, versatile, and cost-effective solutions aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.
iCHOR's Key Achievements & Milestones to Date
iCHOR FOUNDED
iCHOR was conceived in 2014 by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair
iART 510(k) APPROVAL
FDA clearance granted for the 7F iART Mechanical Thrombectomy System
7F LIMITED MARKET RELEASE
iCHOR conducts a 25-patient prospective study to evaluate the safety and efficacy of the 7F iART in a variety of vessels
FIRST iCHOR PATENT GRANTED
iCHOR is granted US patent 11,103,263 B2, Embolectomy System and Methods of Making and Using Same
FDA SUBMISSION FOR 14F iDVT
iCHOR expands the iSWEEP platform, filing a 510(k) for the 14F iDVT system
iDVT 510(k) APPROVAL
FDA clearance granted for the 14F iDVT Mechanical Thrombectomy System
Leadership Team
TIMOTHY BLAIR
CHIEF EXECUTIVE OFFICER
CRAIG BERKY
CHIEF OPERATING OFFICER
TROY LONG, M.D.
CHIEF SCIENCE & TECHNOLOGY OFFICER
JEFF BLAIR
CHAIRMAN
